Literature DB >> 8217214

Comparison of basic fibroblast growth factor in X-linked dystrophin-deficient myopathies of human, dog and mouse.

J E Anderson1, B A Kakulas, P F Jacobsen, R D Johnsen, J N Kornegay, M D Grounds.   

Abstract

Binding of polyclonal antibodies specific for bFGF was examined in tissue sections of myopathic and normal muscles from humans, dogs and mice. The proposal tested was that differences in the amount or distribution of bFGF in muscles of the 3 species, might correlate with the limited muscle regeneration seen in humans and dogs afflicted with x-linked muscular dystrophy, in contrast with the sustained new muscle formation in mdx mice with the homologous myopathy. There was a striking difference between the species in the binding of bFGF antibodies to extracellular matrix, particularly at the periphery of myofibres; binding was pronounced in mouse but weak or absent in human and dog muscle. Binding to muscle nuclei and sarcoplasm was also stronger in mice than in humans and dogs, and in all species was more pronounced in foetal than adult muscle. Increased binding of bFGF antibodies was seen in damaged and regenerating muscle cells in all myopathic specimens where these were present. This was associated with the regenerative process rather than with myopathy, as a similar pattern of bFGF expression was seen in mouse muscle regenerating after experimental crush injury. The higher extracellular staining for bFGF around the periphery of mouse myofibres correlated with the successful muscle regeneration in dystrophic mice. Results suggest that bFGF at the fibre periphery might stimulate a local increase in the numbers of muscle precursor cells which can respond to injury in the mdx mouse.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217214

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  4 in total

Review 1.  The paradox of muscle hypertrophy in muscular dystrophy.

Authors:  Joe N Kornegay; Martin K Childers; Daniel J Bogan; Janet R Bogan; Peter Nghiem; Jiahui Wang; Zheng Fan; James F Howard; Scott J Schatzberg; Jennifer L Dow; Robert W Grange; Martin A Styner; Eric P Hoffman; Kathryn R Wagner
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-02       Impact factor: 1.784

Review 2.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

3.  1,25(OH)(2)vitamin D(3) enhances myogenic differentiation by modulating the expression of key angiogenic growth factors and angiogenic inhibitors in C(2)C(12) skeletal muscle cells.

Authors:  Leah A Garcia; Monica G Ferrini; Keith C Norris; Jorge N Artaza
Journal:  J Steroid Biochem Mol Biol       Date:  2012-09-12       Impact factor: 4.292

4.  Dystrophin-positive muscle fibers following C2 myoblast transplantation into mdx nude mice.

Authors:  Y Hagiwara; Y Mizuno; M Takemitsu; T Matsuzaki; I Nonaka; E Ozawa
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.